Tissue Factor Science
Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications. Learn More function get_style () { return "none"; } function end_ () {
Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications. Learn More function get_style () { return "none"; } function end_ () {
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $108.5M
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | H.I.G. Cap... | higcapital... |
| - | H.I.G. Bio... | higbio.com |
| - | Georgia Re... | gra.org |
| - | H.I.G. Cap... | hig.com/ |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.08.2016 | Series C | $48.5M | - |
| 11.01.2016 | Series C | $40M | - |
| 16.04.2014 | Series B | $20M | - |
Mentions in press and media 11
| Date | Title | Description |
| 14.05.2019 | Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics | VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants I... |
| 10.08.2016 | Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment | - |
| 09.08.2016 | Iconic Therapeutics Raises $48.5M Series C from H.I.G. BioHealth Partners | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced ... |
| 09.08.2016 | Iconic Therapeutics Closes $10M Series C Financing | Iconic Therapeutics, a South San Francisco, CA-based clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, closed an additional $10m Series... |
| 12.01.2016 | Iconic Therapeutics snags $40M for eye disease R&D | Iconic CEO William Greene South San Francisco's Iconic Therapeutics raised $40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with its ocular melanoma program. The round added HBM He... |
| 11.01.2016 | Iconic Therapeutics brings in $40M in Series C for new therapeutics addressing retinal disease and cancer | The financing came from existing investors MPM Capital, H.I.G. Capital and Lundbeckfund Ventures, as well as new contributors HBM Healthcare Investments, Cormorant Asset Management, and Osage University Partners. With this new funding, Icon... |
| 11.01.2016 | Iconic Therapeutics Closes $40M Series C Financing | Iconic Therapeutics, a South San Francisco, CA-based clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, closed a $40m Series C financing... |
| 16.04.2014 | Iconic Therapeutics Completes $20M Series B-1 Equity Financing | Iconic Therapeutics, Inc., a Atlanta, GA and South San Francisco, CA-based biotechnology company focused on developing therapeutics for serious eye disorders, completed a $20m Series B-1 equity financing. Backers included new investors MPM ... |
| 16.04.2014 | Iconic Therapeutics Raises $20M | ATLANTA, GA, Biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing. >> Click here for more funding data on I... |
| 16.04.2014 | Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program | - |
Show more